Therapeutic Options for Management of Endometrial Hyperplasia: An Update
OA: closed
CC0
Limited metadata. Only one source feed has indexed
this record so far — no abstract, full text, or open-access copy is
available through Endo Lab. The
publisher
is the canonical location for the actual content. If you have institutional
access, use "Find at my library".
AI-generated summary
This review discusses current therapeutic options for managing endometrial hyperplasia, focusing on hormonal treatments and surgical interventions.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
My notes (saved in your browser only)
Citation neighborhood (2-hop)
Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. Outer rings show 2-hop neighbours — papers reached through the immediate citers/citees. [ collapse to 1-hop ]
References (100)
- Advances in the management of endometriosis: an update for clinicians via openalex
- Aromatase inhibitor “letrozole” versus progestin “norethisterone” in women with simple endometrial hyperplasia without atypia: A prospective cohort trial via openalex
- Chemokine CCL2 enhances survival and invasiveness of endometrial stromal cells in an autocrine manner by activating Akt and MAPK/Erk1/2 signal pathway via openalex
- Clinical effects of danazol on endometrial hyperplasia in menopausal and postmenopausal women via openalex
- Clinical studies with an antigonadotropin-Danazol via openalex
- Comparison of antiproliferative effects of metformine and progesterone on estrogen-induced endometrial hyperplasia in rats via openalex
- Danazol in the treatment of endometrial hyperplasia via openalex
- Descriptive epidemiology of endometrial hyperplasia in patients with abnormal uterine bleeding via openalex
- Dienogest is as effective as intranasal buserelin acetate for the relief of pain symptoms associated with endometriosis--a randomized, double-blind, multicenter, controlled trial via openalex
- Effect of GnRH analogues on apoptosis and release of interleukin-1beta and vascular endothelial growth factor in endometrial cell cultures from patients with endometriosis via openalex
- Endocrine regulation of menstruation via openalex
- [Endometrial hyperplasias resistant to progestins: alternatives to traditional treatments] via openalex
- Endometrial patterns during danazol and buserelin therapy for endometriosis: comparative structural and ultrastructural study via openalex
- Endometriosis and its treatment with danazol or lupron in relation to ovarian cancer via openalex
- Endometriosis: current therapies and new pharmacological developments via openalex
- Genistein aglycone: a new therapeutic approach to reduce endometrial hyperplasia via openalex
- Hormonal pathology of the endometrium via openalex
- IL-22 in the endometriotic milieu promotes the proliferation of endometrial stromal cells via stimulating the secretion of CCL2 and IL-8 via openalex
- Increased association between endometriosis and endometrial cancer: a nationwide population-based retrospective cohort study via openalex
- Postmenopausal endometrial hyperplasia: role of danazol therapy via openalex
- Progesterone receptor modulators and the endometrium: changes and consequences via openalex
- Prolonged use of gonadotropin-releasing hormone agonist and tibolone as add-back therapy for the treatment of endometrial hyperplasia via openalex
- Risk factors for endometrial hyperplasia: results from a case-control study via openalex
- The effectiveness of danazol therapy in postmenopausal women affected by endometrial hyperplasia via openalex
- The Effect of Medroxyprogesterone Acetate on Angiogenesis in Complex Endometrial Hyperplasia via openalex
- Treatment of endometrial hyperplasia with a danazol-releasing intrauterine device: a prospective study via openalex
- W1992004495 via openalex
- W1992634825 via openalex
- W1992926925 via openalex
- W1993280365 via openalex
- W1994610843 via openalex
- W1995293237 via openalex
- W1997154179 via openalex
- W1998502987 via openalex
- W1999143226 via openalex
- W2000516822 via openalex
- W2001876005 via openalex
- W2003095979 via openalex
- W2004259949 via openalex
- W2004267218 via openalex
- W2004288707 via openalex
- W2005747556 via openalex
- W2009350168 via openalex
- W2013337602 via openalex
- W2015078373 via openalex
- W2017946505 via openalex
- W2018451255 via openalex
- W2020018138 via openalex
- W2021145061 via openalex
- W2024273611 via openalex
- W2025612215 via openalex
- W2025642688 via openalex
- W2026206582 via openalex
- W2026881073 via openalex
- W2030412685 via openalex
- W2030442521 via openalex
- W2030727038 via openalex
- W2030781910 via openalex
- W2031387847 via openalex
- W2033522005 via openalex
- W2037004008 via openalex
- W2038461821 via openalex
- W2044873007 via openalex
- W2045389096 via openalex
- W2048853752 via openalex
- W2050626566 via openalex
- W2051230413 via openalex
- W2052024663 via openalex
- W2054788536 via openalex
- W2057525464 via openalex
- W2058917128 via openalex
- W2059270320 via openalex
- W2061974211 via openalex
- W2064246732 via openalex
- W2067208421 via openalex
- W2067655878 via openalex
- W2068050858 via openalex
- W2068690377 via openalex
- W2069294304 via openalex
- W2072845420 via openalex
- W2072900847 via openalex
- W2073169219 via openalex
- W2076523433 via openalex
- W2079256582 via openalex
- W2079450135 via openalex
- W2079613095 via openalex
- W2080491966 via openalex
- W2082521320 via openalex
- W2085046755 via openalex
- W2085460220 via openalex
- W2091553081 via openalex
- W2093294518 via openalex
- W2093953774 via openalex
- W2094110763 via openalex
- W2096258562 via openalex
- W2097113048 via openalex
- W2100076759 via openalex
- W2101549875 via openalex
- W2102437954 via openalex
- W2103400524 via openalex
Source provenance
- openalex
- last seen: 2026-06-10T17:14:06.276822+00:00
License: CC0
· commercial use OK